Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice.

in

This work identifies tocilizumab, a neutralizing antibody already exploited in clinical applications, as a valuable therapeutic tool in Hutchinson-Gilford progeria, a disease that causes premature ageing. Data here reported further suggest to explore tocilizumab as a potential treatment for aging-related disorders. The study has been designed and coordinated by CNR IGM Bologna Unit.

 

Squarzoni S, Schena E, Sabatelli P, Mattioli E, Capanni C, Cenni V, D’Apice MR, Andrenacci D, Sarli G, Pellegrino V, Festa A, Baruffaldi F, Storci G, Bonafe’ M, Barboni C, Sanapo M, Zaghini A, Lattanzi G. (2021) Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice. Aging Cell, 20(1):e13285. doi: 10.1111/acel.13285